DA Davidson upgraded Phreesia to Buy from Neutral with a price target of $32, up from $30, after assuming coverage of the name. The firm sees a well-built vertical platform for easing chronic problems in healthcare patient engagement, awareness, and payments, and says Phreesia’s Best in KLAS recognition in a market that remains significantly under-digitized can drive net new client adoption and upsell supportive of 20%+ growth, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PHR:
- Barclays starts healthcare technology, distribution with Neutral view
- Phreesia initiated with an Overweight at Barclays
- Accolade named 2024 Digital Health Top Pick, added to Conviction List at Needham
- Phreesia price target lowered by $10 at JPMorgan, here’s why
- Phreesia management to meet virtually with Stephens
